



Corporate Office :
406, Silver Oaks Comm. Complex,
Opp. Arun Society, Paldi,
Ahmedabad-380 007. Gujarat, India.
Phone : 079-26584655
Fax : 079-26588054
CIN No. : L24231GJ2004PLC043861
E-mail : info@sakarhealthcare.com
Web : www.sakarhealthcare.com

14th August, 2023

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400051

Dear Sir,

**Sub: Submission of Unaudited Financial Results & Limited Review Reports (Standalone & Consolidated)
for the quarter ended on 30th June, 2023**

We refer to our letter dated 7th August, 2023 informing the date of Meeting of the Board of Directors of the Company. Please note that the Board of Directors in their meeting held today i.e. 14th August, 2023, have taken on record the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended on 30th June, 2023. These results have been reviewed by the Statutory Auditors of the Company and they have provided their limited review reports dated 14th August, 2023.

We are enclosing herewith copy of the said Unaudited Financial Results and Limited Review Reports.

This is as per Regulation – 33 of the SEBI (LODR) Regulations, 2015.

Please note that the Board meeting commenced at 2:00 PM and concluded at 2:50 PM

Thanking you.

Yours faithfully,
for SAKAR HEALTHCARE LIMITED

BHARAT S. SONI
COMPANY SECRETARY &
COMPLIANCE OFFICER

Encl: As above.

Sakar

Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 Fax: 02717-251621 Email: info@sakarhealthcare.com Web: www.sakarhealthcare.com

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2023

(Rs. In Lakh)

Particulars	Quarter ended on			Previous Year ended on 31-03-2023
	30-06-2023	31-03-2023	30-06-2022	
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
(Refer Notes Below)				
1 Revenue from operations	3898.88	4065.10	2853.39	13335.90
2 Other income	152.08	181.78	40.79	467.48
3 Total Income (1+2)	4050.96	4246.88	2894.18	13803.38
4 Expenses				
a. Cost of Materials consumed	2026.24	2070.00	1645.19	7390.39
b. Purchases of stock-in-trade				
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	90.83	177.28	(50.35)	(35.73)
d. Employee benefits expense	536.49	533.77	320.47	1676.75
e. Finance costs	207.73	215.40	85.86	594.98
f. Depreciation & amortisation expense	451.87	355.44	356.91	1498.60
g. Other expenses	342.74	505.68	142.40	990.27
Total Expenses	3655.90	3857.57	2500.48	12115.26
5 Profit before exceptional items and tax (3-4)	395.06	389.31	393.70	1688.12
6 Exceptional items	-	0.51	-	0.51
7 Profit before tax (5-6)	395.06	388.80	393.70	1687.61
8 Tax expense:				
Current tax	66.23	70.06	68.59	286.98
Deferred tax	111.03	(3.45)	105.85	411.75
MAT Credit Entitlement	(66.23)	(70.06)	(68.59)	(286.98)
9 Profit for the period from continuing operations (7-8)	284.03	392.25	287.85	1275.86
10 Profit from discontinuing operations before Tax	-	-	-	-
11 Tax expense of discontinuing operations	-	-	-	-
12 Profit from Discontinuing operations (after tax) (10-11)	-	-	-	-
13 Profit for the period (9+12)	284.03	392.25	287.85	1275.86

Corporate Office: 406, silver Oaks Commercial Complex, Opp. Arun Society, Paldi, Ahmedabad – 380 007
Phone: 079-26584655 Fax: 079-26588054



Sakar

Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 Fax: 02717-251621 Email: info@sakarhealthcare.com Web: www.sakarhealthcare.com

(Rs. In Lakh)

Particulars	Quarter ended on			Previous Year ended on 31-03-2023
	30-06-2023	31-03-2023	30-06-2022	
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
14 Other Comprehensive Income				
<i>Items that will not be reclassified subsequently to profit or loss</i>				
Re-measurement gains/(losses) on defined benefit plans	(7.37)	(5.24)	(8.08)	(29.49)
Income tax relating to items that will not be reclassified to profit or loss	2.05	1.45	2.25	8.20
<i>Items that will be reclassified subsequently to profit or loss</i>				
Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
Other Comprehensive Income, net of tax	(5.32)	(3.79)	(5.83)	(21.29)
15 Total Comprehensive Income for the period (13+14)	278.71	388.46	282.02	1254.57
16 Paid-up equity shares capital (Face Value per share Rs.10/-)	1904.00	1904.00	1711.80	1904.00
17 Reserves excluding Revaluation Reserves	-	-	-	15217.23
18 Earnings Per Share of Rs. 10/- each (for continuing operations)				
- Basic	1.46	2.04	1.65	6.58
- Diluted	1.46	2.04	1.65	6.58
19 Earnings Per Share of Rs.10/- each (for discontinued operations)				
- Basic	-	-	-	-
- Diluted	-	-	-	-
20 Earnings Per Share of Rs.10/- each (for discontinued & continuing operations)				
- Basic	1.46	2.04	1.65	6.75
- Diluted	1.46	2.04	1.65	6.75



Sakar

Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 Fax: 02717-251621 Email: info@sakarhealthcare.com Web: www.sakarhealthcare.com

Notes:

1	The Company is operating only in one segment. Hence segment reporting is not given.
2	The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
3	The Company has a wholly owned subsidiary vis. M/s. Sakar Oncology Private Limited. Other than this, the Company does not have any subsidiary/ associate.
4	Provision for taxation/deferred taxation, if any, will be made at the year end.
5	Figures, wherever required, are regrouped / rearranged.
6	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 14 th August, 2023

Date: 14th August, 2023
Place: Ahmedabad



for SAKAR HEALTHCARE LIMITED


SANJAY S. SHAH
MANAGING DIRECTOR
(DIN : 01515296)



STANDALONE LIMITED REVIEW REPORT

Review Report to the Board of Directors of Sakar Healthcare Limited


We have reviewed the accompanying statement of unaudited standalone financial results of Sakar Healthcare Limited for the period ended 30th June 2023 ("the statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, as amended ("the Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement(s). A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For J S Shah & Co
Chartered Accountants
(Firm's Registration No. 132059W)


Jaimin S Shah

Partner

(Membership No. 138488)

(UDIN: 23138488BGSXTF4873)

Place: Ahmedabad

Date: 14-08-2023



**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS
FOR THE QUARTER ENDED ON 30TH JUNE, 2023**

(Rs. In lakh)

Particulars		Quarter ended on			Previous Year ended on 31-03-2023
		30-06-2023	31-03-2023	30-06-2022	
(Refer Notes Below)		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from operations	3898.88	4065.10	2853.39	13335.90
2	Other income	152.08	181.78	40.79	467.48
3	Total Income (1+2)	4050.96	4246.88	2894.18	13803.38
4	Expenses				
	a. Cost of Materials consumed	2026.24	2070.00	1645.19	7390.39
	b. Purchases of stock-in-trade	-	-	-	-
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	90.83	177.28	(50.35)	(35.73)
	d. Employee benefits expense	536.49	533.77	320.47	1676.75
	e. Finance costs	207.73	215.40	85.86	594.98
	f. Depreciation & amortisation expense	451.87	355.44	356.91	1498.60
	g. Other expenses	342.74	505.68	142.40	990.27
	Total Expenses	3655.90	3857.57	2500.48	12115.26
5	Profit before exceptional items and tax (3-4)	395.06	389.31	393.70	1688.12
6	Exceptional items	-	0.51	-	0.51
7	Profit before tax (5-6)	395.06	388.80	393.70	1687.61
8	Tax expense:				
	Current tax	66.23	70.06	68.59	286.98
	Deferred tax	111.03	(3.45)	105.85	411.75
	MAT Credit Entitlement	(66.23)	(70.06)	(68.59)	(286.98)
9	Profit for the period from continuing operations (7-8)	284.03	392.25	287.85	1275.86
10	Profit from discontinuing operations before Tax	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-
12	Profit from Discontinuing operations (after tax) (10-11)	-	-	-	-
13	Profit for the period (9+12)	284.03	392.25	287.85	1275.86
	Attributable to owner of parent	284.03	392.25	287.85	1275.86
	Attributable to Non-controlling interests				



Sakar

Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 Fax: 02717-251621 Email: info@sakarhealthcare.com Web: www.sakarhealthcare.com

Particulars	Quarter ended on			Previous Year ended on 31-03-2023
	30-06-2023	31-03-2023	30-06-2022	
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
14 Other Comprehensive Income				
<i>Items that will not be reclassified subsequently to profit or loss</i>				
Re-measurement gains/(losses) on defined benefit plans	(7.37)	(5.24)	(8.08)	(29.49)
Income tax relating to items that will not be reclassified to profit or loss	2.05	1.45	2.25	8.20
<i>Items that will be reclassified subsequently to profit or loss</i>				
Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
Other Comprehensive Income, net of tax	(5.32)	(3.79)	(5.83)	(21.29)
Attributable to owner of parent	(5.32)	(3.79)	(5.83)	(21.29)
Attributable to Non-controlling interests				
15 Total Comprehensive Income for the period (13+14)	278.71	388.46	282.02	1254.57
Attributable to owner of parent	278.71	388.46	282.02	1254.57
Attributable to Non-controlling interests				
16 Paid-up equity shares capital (Face Value per share Rs. 10/-)	1904.00	1904.00	1711.80	1904.00
17 Reserves excluding Revaluation Reserves				15430.71
18 Earnings Per Share of Rs.10/- each (for continuing operations)				
- Basic	1.46	2.04	1.65	6.59
- Diluted	1.46	2.04	1.65	6.59
19 Earnings Per Share of Rs.10/- each (for discontinued operations)				
- Basic	-	-	-	-
- Diluted	-	-	-	-
20 Earnings Per Share of Rs.10/- each (for discontinued & continuing operations)				
- Basic	1.46	2.04	1.65	6.59
- Diluted	1.46	2.04	1.65	6.59



Sakar

Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 Fax: 02717-251621 Email: info@sakarhealthcare.com Web: www.sakarhealthcare.com

Notes:

1	The Company is operating only in one segment. Hence segment reporting is not given.
2	The consolidated Unaudited financial results of the Company are comprising of its subsidiary M/s. Sakar Oncology Private Limited.
3	The Consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 “Interim Financial Reporting” as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
4	Provision for taxation/deferred taxation, if any, will be made at the year end.
5	Figures, wherever required, are regrouped / rearranged.
6	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 14 th August, 2023

for SAKAR HEALTHCARE LIMITED

Date: 14th August, 2023

Place: Ahmedabad




SANJAY S. SHAH
MANAGING DIRECTOR
(DIN : 01515296)



CONSOLIDATED LIMITED REVIEW REPORT

TO THE BOARD OF DIRECTORS OF SAKAR HEALTHCARE LIMITED


1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **Sakar Healthcare Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/ (loss) after tax and total comprehensive income / loss of its associates and joint ventures for the quarter ended 30th June 2023 and for the period from 01.04.2023 to 30.06.2023 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 31st March 2023 and the corresponding period from 01.04.2022 to 31.03.2023 as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS-34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entity:

1. Sakar Oncology Private Limited.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the branch auditors and other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.




6 We did not audit the financial statements and other financial information, in respect of Subsidiary, whose interim financial information reflects total revenues of Rs. Nil , total net profit after tax of Rs. Nil and total comprehensive income of Rs Nil for the quarter ended June 30 2022. These interim financial information have been audited by other auditors, auditor's reports have been furnished to us by the management. Our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiary , and our report in terms of sub-sections(3) of section 143 of the Act, in so far as it relates to the aforesaid subsidiary, is based solely on the reports of such other auditors. and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters

For J S Shah & Co
Chartered Accountants
(Firm's Registration No. 132059W)



Place: Ahmedabad
Date: 14-08-2023


Jaimin S Shah
Partner
(Membership No. 138488)
(UDIN: 23138488BGSXTG1469)